The Calmer Co has posted a record $2.01 million in sales for Q2 FY26, propelled by a 9% increase in US revenue which now accounts for over half of the group’s total income. Strong retail and wholesale growth underpin the company’s expanding footprint in the natural relaxation market.
- Record Q2 FY26 sales of $2.01 million
- US sales exceed $1 million, representing 51% of total revenue
- Retail sales up 42% year-on-year
- Wholesale revenue grows 15% quarter-on-quarter
- Strong cash position with $1.03 million on hand and additional financing secured
Record-Breaking Quarter
The Calmer Co has delivered a standout performance in the second quarter of fiscal 2026, reporting total sales of $2.01 million; a new record for the natural relaxation company. This milestone reflects a continuation of the company’s upward trajectory, driven largely by strong growth in the United States, which now accounts for more than half of the group’s revenue.
US sales climbed 9% quarter-on-quarter to $1.01 million, marking the first time the company has surpassed the $1 million mark in a single quarter in this key market. This growth was fuelled by expanding product offerings on Amazon Marketplace, including tinctures, capsules, and flavoured kava shots, alongside a 15% increase in wholesale revenue to $362,000. The wholesale channel’s strength is particularly notable, with repeat orders from established customers and new B2B partnerships, including sales of the company’s CO₂ extract to a US beverage partner.
Retail and E-Commerce Momentum
Retail sales also showed robust growth, rising 42% compared to the prior corresponding period to $743,000. The company’s Fiji-sourced kava products have gained significant traction in mainstream Australian retail, with key products ranking highly in the stress relief category. E-commerce remains the largest sales channel, generating $905,000 or 45% of total group revenue. Amazon USA continues to be a critical platform, delivering $652,000 in revenue and maintaining its position as the company’s largest marketplace.
Direct-to-consumer sales contributed $252,000, supported by ongoing investments in advertising and website optimisation. The company is preparing for further growth in e-commerce with planned product range expansions and new product launches pending regulatory approval.
Financial Health and Growth Outlook
Financially, The Calmer Co remains disciplined, closing the quarter with $1.03 million in cash and securing an additional $700,000 tranche of convertible notes shortly after quarter-end. Inventory levels are stable, with new product formats already stocked in the US warehouse. Subscription sales are also on the rise, with $280,000 of inventory presold through monthly subscriptions, highlighting a growing recurring revenue stream.
CEO Zane Yoshida emphasised the company’s confidence in the US market’s potential, noting that year-to-date revenue has already surpassed the full-year results of FY25. The company’s strategic focus on premium, traceable kava products sourced from the Pacific Islands continues to resonate with consumers, positioning The Calmer Co well for sustained expansion.
Bottom Line?
With US sales momentum accelerating and new product launches on the horizon, The Calmer Co is poised for further growth but must maintain execution to capitalise on its expanding market presence.
Questions in the middle?
- How will upcoming product launches impact sales growth in the US and other markets?
- Can The Calmer Co sustain its wholesale momentum amid increasing competition?
- What are the company’s plans to scale subscription offerings and RTD beverages?